
Repeat: Treatment.com AI Announces New Medical Education Suite to Enhance Clinical Skills Training Through AI-Simulated Patients
VANCOUVER, BC, June 11, 2025 (GLOBE NEWSWIRE) —
Treatment.com
AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) ('Treatment') is pleased to announce that it has released its latest version of the Medical Education Suite (MES). The University of Minnesota Medical School has successfully completed a live deployment of
Treatment.com
AI's new Medical Education Suite (MES), an AI-powered clinical skills assessment platform designed to support medical schools in delivering scalable, rigorous, and cost-effective Objective Structured Clinical Examinations (OSCEs).
The deployment, conducted with over 240 third-year medical students, marked the first large-scale implementation of computer-simulated patient cases developed through the Global Library of Medicine (GLM), a clinician-built medical knowledge engine. The exams ran with complete technical reliability during deployment, as well as integrating seamlessly into the school's existing OSCE workflow.
'Our goal is to support medical schools by applying our clinical experience and AI expertise to real educational challenges.' stated Dr. Kevin Peterson, Founder and Chief Medical Officer of
Treatment.com
AI. 'The Medical Education Suite reflects years of development in diagnostic reasoning and knowledge engineering. By introducing structured, AI-simulated patients alongside live simulated patients, and offering objective real-time scoring, we're helping students build stronger clinical skills in the classroom and giving educators the trusted healthcare education software needed to teach and assess clinical content and behavioral approaches to complex clinical problems with confidence.'
The MES is a scalable platform designed to reduce administrative and faculty time, improve objectivity, increase evaluation consistency, and provide a robust digital infrastructure to support both live and AI-simulated formats. The focus of the platform is to help enhance the clinical skills of our next generation of healthcare professionals. By incorporating curated AI-generated cases and the supportive services provided by Treatment, the system enables:
'Partnering with
Treatment.com
AI gave us the opportunity to explore how clinically governed AI can strengthen the way we assess and support student learning. The MES allowed us to deliver a high-stakes OSCE at scale, while ensuring consistent, objective evaluation aligned with our academic standards. The MES represents a meaningful step forward in the evolution of medical education.' said Professor Claudio Violato, Assistant Dean, University of Minnesota Medical School. 'We look forward to sharing our findings.'
The MES combines AI-simulated patients with automated feedback, helping faculty assess diagnostic and management reasoning, clinical prioritization, and documentation quality, all mapped to learning objectives. Early feedback suggests that the platform enhances the student learning experience and strengthens the reliability of OSCE results.
Preliminary results of the accuracy and precision of the GLM as applied in the MES platform were presented at the AAMC's 2025 Group on Information Resources meeting. Prof. Violato, Dr. Peterson, and their respective teams are preparing further scientific publications detailing the methodology, deployment, and outcomes of the UMN program.
Treatment.com AI is engaging with a wide variety of other schools, with the goal to extend the MES offering across North America, the UK, and to other international OSCE markets.
About
Treatment.com
AI Inc.
Treatment.com AI is a company utilizing AI (artificial intelligence) and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally,
Treatment.com
AI has built a comprehensive, personalized healthcare AI engine — the Global Library of Medicine (GLM). With more than 10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals as well as providing recommended tests (physical and lab), imaging and billing codes. The GLM helps healthcare professionals (doctors, nurses or pharmacists) reduce their administrative burden; creates more time for needed face-to-face patient appointments; and enables greater consistency in quality of patient support.
Treatment.com
AI's GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities.
Learn more at:
or contact
.
About University of Minnesota Medical School
Founded in 1888, the University of Minnesota Medical School is one of the nation's largest, with three campuses in Minneapolis, Duluth, and St. Cloud. It enrolls first- and second-year students at Duluth and St. Cloud, and carries clinical training at the Twin Cities campus and affiliated hospitals. The school educates future physicians through MD, graduate, undergraduate, and continuing professional development programs, supported by over 3,000 faculty members and 20+ research centers and institutes. Its core mission is to improve health through exceptional education, compassionate patient care, and leading-edge biomedical research, particularly focusing on primary care, specialty medicine, rural communities, and American Indian/Alaska Native populations. The school is nationally recognized for its NIH-funded research (ranked #21 overall, #2 among public medical schools) and emphasizes interprofessional, community-based training while promoting equity and access across diverse populations.
Learn more at:
FOR ADDITIONAL INFORMATION, CONTACT:
Dr. Essam Hamza, CEO –
Treatment.com
AI Inc.
Email:
Media inquiries:
treatment.com
Sales:
Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955
Cautionary Statement
This news release contains forward-looking statements that are based on
Treatment.com
AI's expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although
Treatment.com
AI believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and
Treatment.com
undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Citi Expresses Optimism for Eli Lilly and Company (LLY)
Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Long Term Growth Stocks to Invest in Right Now. On June 25, Citi reported that 'compelling' data shows that Eli Lilly and Company (NYSE:LLY) and Novo Nordisk (NVO) have turned obesity into a treatable disease from a lifestyle-based condition. The firm models more than $40 billion in obesity sales by 2030, well above the consensus estimates of $25 billion. Citi stated that as the obesity space evolves from injectables to convenient orals, such as orforglipron, the emergence of a 'dynamic' consumer-centric market is possible, and LillyDirect by Eli Lilly and Company (NYSE:LLY) is well-positioned to connect high consumer visibility for orforglipron with global access. In a research note, Citi further stated that it estimated penetration rates via income-based tiers for pricing and out-of-pocket costs in low- and mid-body mass index patients. The results place Eli Lilly and Company's (NYSE:LLY) consumer platform opportunity at $15B, which is not assumed in the firm's model. It thus believes that Eli Lilly and Company's (NYSE:LLY) is in a position to expedite access outside the US, employing a centralized out-of-pocket payment model instead of the traditional country-by-country launch. It contended that an 'income-based tiered pricing of orforglipron via LillyDirect could unlock unprecedented volume, all the while allowing it to maintain overall pricing power.' Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies. Investors are bullish on Eli Lilly and Company (NYSE:LLY) due to its in-demand GLP-1 drugs, used to treat diabetes and obesity, which are still in their early growth stages, and the company's strong financials. While we acknowledge the potential of LKQ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
a day ago
- Yahoo
Citi Expresses Optimism for Eli Lilly and Company (LLY)
Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Long Term Growth Stocks to Invest in Right Now. On June 25, Citi reported that 'compelling' data shows that Eli Lilly and Company (NYSE:LLY) and Novo Nordisk (NVO) have turned obesity into a treatable disease from a lifestyle-based condition. The firm models more than $40 billion in obesity sales by 2030, well above the consensus estimates of $25 billion. Citi stated that as the obesity space evolves from injectables to convenient orals, such as orforglipron, the emergence of a 'dynamic' consumer-centric market is possible, and LillyDirect by Eli Lilly and Company (NYSE:LLY) is well-positioned to connect high consumer visibility for orforglipron with global access. In a research note, Citi further stated that it estimated penetration rates via income-based tiers for pricing and out-of-pocket costs in low- and mid-body mass index patients. The results place Eli Lilly and Company's (NYSE:LLY) consumer platform opportunity at $15B, which is not assumed in the firm's model. It thus believes that Eli Lilly and Company's (NYSE:LLY) is in a position to expedite access outside the US, employing a centralized out-of-pocket payment model instead of the traditional country-by-country launch. It contended that an 'income-based tiered pricing of orforglipron via LillyDirect could unlock unprecedented volume, all the while allowing it to maintain overall pricing power.' Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies. Investors are bullish on Eli Lilly and Company (NYSE:LLY) due to its in-demand GLP-1 drugs, used to treat diabetes and obesity, which are still in their early growth stages, and the company's strong financials. While we acknowledge the potential of LKQ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio


Miami Herald
a day ago
- Miami Herald
New to The Street Announces the Broadcast of Show Number 675 This Saturday at 6:30 PM EST on Bloomberg Television Featuring: FLOKI, BioVie (NASDAQ: BIVI), Arrive AI ($ARAI), Health In Tech (NASDAQ HIT), and Commercialville T.V.
Show Number 675 is sponsored programming by Ainos (NASDAQ: AIMD), Arrive AI ($ARAI), Acurx Pharmaceuticals (NASDAQ: ACXP), Sustainable Green Team (OTC: SGTM) and Commercialville T.V. commercials NEW YORK CITY, NEW YORK / ACCESS Newswire / June 27, 2025 / New to The Street proudly announces the broadcast of Show Number 675, airing this Saturday at 6:30 PM EST on Bloomberg Television. Show Number 675 marks a major milestone for the nationally syndicated program known for its in-depth interviews and business features spanning emerging technologies, biotech, fintech, and media. Show Number 675 will feature the following companies: FLOKI - A leading Web3 utility and metaverse token with a growing ecosystem across blockchain, education, and decentralized Inc. (NASDAQ:BIVI) - A clinical-stage biotech company advancing therapeutic solutions for Alzheimer's and advanced liver AI ($ARAI) - A next-generation logistics platform utilizing AI to streamline smart deliveries and mail In Tech - A digital health platform transforming underwriting and broker tools for next-gen insurance T.V. -CommercialVille T.V. is an innovative, zip‑code‑targeted, video‑based search engine designed specifically for local advertising. Using its patented technology, it delivers location‑relevant video ads directly to users based on entered zip codes and keywords. Show Number 675 is sponsored programming brought to audiences by: Ainos, Inc. (NASDAQ:AIMD) - Focused on developing innovative point-of-care diagnostics and therapeutic monitoring AI ($ARAI) - Disrupting traditional logistics with AI-powered predictive Pharmaceuticals, Inc. (NASDAQ:ACXP) - Developing a new class of antibiotics addressing multidrug-resistant Gram-positive T.V. - Blending entertainment and e-commerce into a measurable media platform. Vince Caruso, CEO and C0 Founder of New to The Street, commented: Show Number 675 will also stream on the New to The Street YouTube channel (2.9M+ subscribers), and be shared across social media and digital distribution networks globally. For media, sponsorship, or interview inquiries related to Show Number 675:Monica BrennanMonica@ About New to The StreetSince 2009, New to The Street has produced over 675 episodes, airing weekly on Bloomberg Television and Fox Business as sponsored programming. Known for combining linear TV with digital media, social amplification, and billboard coverage, New to The Street provides a powerful media platform for public and private companies looking to elevate their visibility. SOURCE: New To The Street